{"id":13446,"date":"2022-11-30T11:12:00","date_gmt":"2022-11-30T11:12:00","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/?post_type=journal-paper&p=13446"},"modified":"2026-01-30T11:21:26","modified_gmt":"2026-01-30T11:21:26","slug":"discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation","status":"publish","type":"journal-paper","link":"https:\/\/www.sygnaturediscovery.com\/fr\/journal-paper\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\/","title":{"rendered":"Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation"},"content":{"rendered":"\n

Andrew Novak, David Laughton, Rebecca Lane, Emma Blackham, Jennifer Thomas, Elli Chatzopoulou, Joseph Wrigglesworth, Abdul Quddus, Saleh Ahmed, David Cousin, Lorna Duffy, Nathalie Dubois, John Unitt, Katalin Orban, Edward Browne, Michelle Ward, David Mycock, Maria Ieva, Nicholas Bland<\/strong>, Pascal George, Timothy Bourne, H\u00e9l\u00e8ne Asnagli, Louise Birchm, Geraint Jones<\/strong><\/p>\n\n\n\n

Abstract<\/strong><\/p>\n\n\n\n

Herein, we report the discovery of a first-in-class chemotype 2-(alkylsulfonamido)thiazol-4-yl)acetamides that act as pan-selective inhibitors of cytidine 5\u2032-triphosphate synthetase (CTPS1\/2), critical enzymes in the de novo<\/em> pyrimidine synthesis pathway. Weak inhibitors identified from a high-throughput screening of 240K compounds have been optimized to a potent, orally active agent, compound 27<\/strong>, which has shown significant pharmacological responses at 10 mg\/kg dose BID in a well-established animal model of inflammation.<\/p>\n\n\n\n

Ref: J Med Chem 2022<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"featured_media":0,"template":"","category":[681,682,679,713],"resource_tag":[],"class_list":["post-13446","journal-paper","type-journal-paper","status-publish","hentry","category-bioscience","category-chemistry","category-computer-aided-drug-design","category-medicinal-chemistry"],"acf":[],"yoast_head":"\nDiscovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation - Sygnature<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/journal-paper\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation - Sygnature\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/journal-paper\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-30T11:21:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/02\/sygnature-hit-to-lead-team-collaboration-scaled.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/journal-paper\\\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/journal-paper\\\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\\\/\",\"name\":\"Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation - Sygnature\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"datePublished\":\"2022-11-30T11:12:00+00:00\",\"dateModified\":\"2026-01-30T11:21:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/journal-paper\\\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/journal-paper\\\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/journal-paper\\\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/page-daccueil\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation - Sygnature","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/journal-paper\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\/","og_locale":"fr_CA","og_type":"article","og_title":"Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation - Sygnature","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/journal-paper\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\/","og_site_name":"Sygnature","article_modified_time":"2026-01-30T11:21:26+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2026\/02\/sygnature-hit-to-lead-team-collaboration-scaled.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/journal-paper\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/journal-paper\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\/","name":"Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation - Sygnature","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"datePublished":"2022-11-30T11:12:00+00:00","dateModified":"2026-01-30T11:21:26+00:00","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/journal-paper\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/journal-paper\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/journal-paper\/discovery-and-optimization-of-potent-and-orally-available-ctp-synthetase-inhibitors-for-use-in-treatment-of-diseases-driven-by-aberrant-immune-cell-proliferation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/page-daccueil\/"},{"@type":"ListItem","position":2,"name":"Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation"}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/journal-paper\/13446","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/journal-paper"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/journal-paper"}],"version-history":[{"count":0,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/journal-paper\/13446\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=13446"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=13446"},{"taxonomy":"resource_tag","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/resource_tag?post=13446"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}